<DOC>
	<DOCNO>NCT03048058</DOCNO>
	<brief_summary>An investigator-blinded , prospective , 6 month study subject persistent erythema associate active rosacea conduct 20 subject age 18 year old . All subject receive standard-of-care brimonidine topical gel , 0.33 % instruction apply daily per package insert . Adherence assess use weekly internet survey document often medication use , well reminder rosacea trigger general use brimonidine .</brief_summary>
	<brief_title>Internet Surveys Their Impact Adherence Rosacea</brief_title>
	<detailed_description>An investigator-blinded , prospective , 6 month study subject persistent erythema associate active rosacea conduct 20 subject age 18 year old . All subject receive standard-of-care brimonidine topical gel , 0.33 % instruction apply daily per package insert . Adherence assess use weekly internet survey document often medication use , well reminder rosacea trigger general use brimonidine.Subjects randomize 1:1 weekly internet survey group standard care non-survey group . At visit , review internet survey use do assess adherence medication . . Disease severity measure ( ( Clinician 's Erythema Assessment ( CEA ) , Lesion count obtain . QOL measure .</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>Male female subject persistent erythema associate rosacea , age great 18 , agree participate provide write consent . Have Investigator Global Assessment mild moderate rosacea ( IGA rating 2 5 Investigator Global Assessment score include erythema assessment ) . Access computer internet . Initiation change dose within 4 week baseline systemic anti‚Äêinflammatory medication may influence study outcome . Use topical therapy rosacea within 2 week baseline . Use systemic corticosteroid within 4 week baseline . Presence concurrent medical condition skin condition , determine investigator potentially interfere study outcome patient assessment . Subjects know allergy sensitivity bromonidine topical gel , 0.33 % component therein . Female subject postmenopausal least 1 year , surgically sterile , willing practice effective contraception study . Nursing mother , pregnant woman woman plan become pregnant study exclude . Subjects severe cardiovascular disease vascular insufficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>